StimOxyGen
Pre-clinicalIn solid tumours the development of hypoxia leads to enhanced tumour survival and decreased efficacy of cancer treatments such as radiotherapy, some forms of chemotherapy and emerging sensitiser-based approaches that depend on oxygen for maximum efficacy. Addressing tumour hypoxia remains a clinical unmet need.
Founded
2017
Focus
Nanotechnology
About
In solid tumours the development of hypoxia leads to enhanced tumour survival and decreased efficacy of cancer treatments such as radiotherapy, some forms of chemotherapy and emerging sensitiser-based approaches that depend on oxygen for maximum efficacy. Addressing tumour hypoxia remains a clinical unmet need.
Company Info
TypePrivate
Founded2017
LocationLondon, United Kingdom
StagePre-clinical
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile